Enveric Biosciences Inc./$ENVB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
- Ticker
- $ENVB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 6
- Headquarters
- Cambridge, United States
- Website
- www.enveric.com
ENVB Metrics
BasicAdvanced
$6.7M
-
-$7.48
1.11
-
Price and volume
Market cap
$6.7M
Beta
1.11
52-week high
$13.25
52-week low
$1.17
Average daily volume
48K
Financial strength
Current ratio
10.207
Quick ratio
9.63
Interest coverage (TTM)
-15,286.30%
Profitability
EBITDA (TTM)
-8.575
Management effectiveness
Return on assets (TTM)
-87.34%
Return on equity (TTM)
-170.04%
Valuation
Price to book
0.73
Price to tangible book (TTM)
0.73
Price to free cash flow (TTM)
-0.281
Free cash flow yield (TTM)
-355.69%
Free cash flow per share (TTM)
-5.3
Growth
Earnings per share change (TTM)
-91.19%
3-year earnings per share growth (CAGR)
-84.52%
ENVB Financial Performance
Revenues and expenses
ENVB Earnings Performance
Company profitability
Upcoming events
No upcoming events
ENVB News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.